M2NPs selectively delivered anti-colony stimulating factor-1 receptor (anti-CSF-1R) siRNA to M2-like TAMs and eliminated 52% of M2-like TAMs, resulting in 87% reduction in melanoma tumor volume and prolonged survival, indicating that an immune memory that inhibits tumor recurrence was established. This evidence concerns the gene CSF1R and melanoma.